(Z) -Orantinib

(Z) -Orantinib ((Z) -SU6668) is an effective, selective, orally active, ATP-competitive inhibitor of Flk-1/KDR, PDGFRβ, and FGFR1 with IC50 values of 2.1, 0.008, and 1.2 μM, respectively. As a potent anti-angiogenic and anti-tumor compound, (Z) -Orantinib ((Z) -SU6668) induces significant regression in established tumors. (Z) -Orantinib serves as a valuable tool for investigating tumor angiogenesis inhibition mechanisms, tumor microenvironment regulation, and targeted anti-cancer strategy development, providing highly reliable experimental support for exploring solid tumor drug mechanisms and drug screening.